Development and Regulatory Aspects of Topical Dermatics Today
Organizer:
GD Society for Dermopharmacy
in cooperation with
BfArM Federal Institute for Drugs abd Medical Devices
Program (PDF)
Session 1: Dermatics - a world of its own
Session
2: Identification and production of active pharmaceutical ingredients
Session
3: Characterization of active pharmaceutical ingredients
Session 4: Aspects of formulation
Session 5: Clinical developmentSession 1: Dermatics - a world of its own
Session 2: Identification and production of active pharmaceutical ingredients
| Titel | Author |
| Abstracts of sessions 1 and 2 | |
| Which dermatics do we have? | H. F. Merk, Aachen |
| Which dermatics do we need? |
T. Luger, Münster |
| The regulatory framework for preclinical research |
T. Zapf, Bonn |
| Target identification: general aspects and sphingosine-1-phosphate receptors as an example | B. Kleuser, Potsdam |
| Lead optimization: general aspects and MAP kinase inhibitors for psoriasis as an example | S. Laufer, Tübingen |
| Target identification and lead optimization: Fungal secreted aspartic proteinase inhibitors as a paradigm | C. Borelli, München |
| Production of active pharmaceutical ingredients: general aspects and sphingosine-1-phosphate and inhibitors of human polymerase alpha as an example | R. Zuhse, Luckenwalde |
| Author | Titel |
| Abstracts of sessions 1 and 2 | |
| C. Borelli, München | Target identification and lead optimization: Fungal secreted aspartic proteinase inhibitors as a paradigm |
| B. Kleuser, Potsdam | Target identification: general aspects and sphingosine-1-phosphate receptors as an example |
| S. Laufer, Tübingen | Lead optimization: general aspects and MAP kinase inhibitors for psoriasis as an example |
| T. Luger, Münster | Which dermatics do we need? |
| H. F. Merk, Aachen | Which dermatics do we have? |
| T. Zapf, Bonn | The regulatory framework for preclinical research |
| R. Zuhse, Luckenwalde | Production of active pharmaceutical ingredients: general aspects and sphingosine-1-phosphate and inhibitors of human polymerase alpha as an example |
Session 3: Characterization of active pharmaceutical ingredients
Session 4: Aspects of formulation
| Titel | Author |
| Abstracts for sessions 3 and 4 |
|
| Toxicological characterization of new active pharmaceutical ingredients for dermatics |
G. Hager, Tutzing |
| Pharmacological characterization of new active ingredients |
T. Zollner, Berlin |
| Regulatory aspects of pharmaceutical quality with dermatics |
B. Tofern-Reblin, Bonn |
| Optimizing conventional galenics: microemulsions as a paradigm | P. Schlupp, Gießen |
| Author | Titel |
| Abstracts for sessions 3 and 4 | |
| G. Hager, Tutzing | Toxicological characterization of new active pharmaceutical ingredients for dermatics |
| P. Schlupp, Gießen | Optimizing conventional galenics: microemulsions as a paradigm |
| B. Tofern-Reblin, Bonn | Regulatory aspects of pharmaceutical quality with dermatics |
| T. Zollner, Berlin | Pharmacological characterization of new active ingredients |
top
Session 5: Clinical development
| Titel | Author |
| Abstracts of session 5 |
|
| Optimizing the development plan through scientific advice process |
J. Regenold, Badenweiler |
| Human toxicology/phase I studies |
J. Fluhr, Berlin |
| Phase II trials |
B. Hughes-Formella, Hamburg |
| Phase III trials | K.-P. Wilhelm, Schenefeld |
| Phase IV trials | E. Blümner, Frankfurt am Main |
| Author | Titel |
| Abstracts of session 5 | |
| E. Blümner, Frankfurt am Main | Phase IV trials |
| J. Fluhr, Berlin | Human toxicology/phase I studies |
| B. Hughes-Formella, Hamburg | Phase II trials |
| J. Regenold, Badenweiler | Optimizing the development plan through scientific advice process |
| K.-P. Wilhelm, Schenefeld | Phase III trials |
Copyright
© 2000 - 2024
Institute for Dermopharmacy GmbH
webmaster@gd-online.de
Haftungsausschluss